ClinicalTrials.gg
Not yet recruitingNCT07870889Updated Oct 13, 2026

Vortosiran in Atrial Fibrillation

A Phase 2 interventional study of Vortosiran and Vortosiran in Non-valvular Atrial Fibrillation (AF), sponsored by Ribocure Pharmaceuticals AB. Not yet recruiting at 15 sites in 4 countries. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Ribocure Pharmaceuticals AB (part of Suzhou Ribo Life Science Co., Ltd.) · Phase 2, Interventional, and Treatment

Updated Oct 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
45 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing apixaban in Atrial Fibrillation — 11 open to participants now, 12 under way, 4 of them phase 3. apixaban · Atrial Fibrillation.

Planned enrollment
22nd of 31
150 · median 586
Started
2026
with 5 others
Phase 2
4 of 31
1 open now
Primary completion
2028-07
later than 5 of 11 live
Registered
31st of 31
by date

Among the 31 studies testing apixaban in Atrial Fibrillation, this one is the 22nd largest by planned enrollment, is one of 6 that started in 2026, is one of 4 in phase 2, reaches primary completion later than 5 of the 11 other live ones, and was the 31st registered.

Atrial Fibrillation

4,016 studies on the registry are indexed under Atrial Fibrillation; 964 are open to participants now.

Browse Atrial Fibrillation studies →

Open to participants now

11 of the 31 studies testing apixaban in Atrial Fibrillation are open now, in 10 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About apixaban

apixaban: first FDA approval 2012 (ELIQUIS), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 610 Atrial Fibrillation studies recruiting now, 407 (67%) set no upper age limit and 43 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.

This study: 45 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing apixaban in Atrial Fibrillation, or all of them as a file.
02

Study summary

This is a randomised, actively controlled Phase IIb trial to evaluate the safety and pharmacodynamics (PD) of two blinded doses of subcutaneously administered vortosiran and open-label apixaban in patients with AF.

The trial consists of three groups including 50 participants each. The participants will be randomized to either the low dose group or the high dose group receiving vortosiran or to the group receiving apixaban. The treatment will be open-label for vortosiran vs apixaban. The vortosiran dose will be blinded to patients and investigators.

Both the low- and the high-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, at the end of the vortosiran treatment period, the participants will start an open-label part of the trial and will be switched to standard-of-care apixaban treatment until Week 64 (End of Trial; EOT). Participants in the open-label apixaban arm will receive apixaban as standard of care during the entire trial.

Read the detailed description

Atrial fibrillation (AF) is among the most prevalent cardiovascular conditions, affecting approximately 2 4% of the adult population worldwide. AF represents the most common sustained supraventricular arrhythmia and is associated with substantial morbidity, mortality, and health-care burden. Patients with AF are at an elevated risk of thromboembolic complications, particularly ischemic stroke and systemic embolism, while also facing an increased risk of bleeding associated with long-term antithrombotic therapy administered to prevent these complications. The principal aim of management in AF is to prevent stroke while minimizing haemorrhagic risk through careful risk stratification for both thromboembolic risk and bleeding risk, and informed and individualised treatment selections.

According to current guideline recommendations, oral anticoagulation is recommended for stroke prevention and may be guided by CHA2DS2 -VASc clinical risk assessment tool. Nonvitamin K antagonist oral anticoagulants (NOACs, also referred to as direct oral anticoagulants, or DOACs) are preferred over vitamin K antagonists (VKAs) in most cases due to their superior safety profile and lower incidence of intracranial bleeding. Bleeding risk can be assessed using validated tools such as HAS-BLED, and modifiable risk factors should be addressed to reduce overall treatment-related complications.

Despite a superior efficacy-safety profile of NOACs relative to VKAs, patients treated with NOACs remain at residual risk for stroke, systemic embolism, and cardiovascular mortality. Furthermore, although NOACs are associated with reduced rates of intracranial haemorrhage compared with VKAs, they still confer a considerable risk of major bleeding and clinically relevant non-major bleeding events. Consequently, the clinical need for strategies that further optimize the balance between thromboembolic prevention and bleeding risk in patients with AF remains.

Recent advances have positioned coagulation factor XI (FXI) inhibition as a promising strategy in anti-thrombotic drug development. FXI is a crucial element of the intrinsic coagulation pathway, and genetic FXI deficiency (haemophilia C) is typically associated with only mild bleeding even in complete deficiency, suggesting the potential for improved safety compared to conventional anti-thrombotic drugs by disengaging physiologic haemostasis from pathologic, intraluminal thrombosis. FXI inhibition reliably prolongs activated partial thromboplastin time (APTT) in vitro, and epidemiological studies demonstrate that inherited FXI deficiency confers protection against venous thromboembolism (VTE) and ischemic stroke. Conversely, elevated circulating activated FXI (FXIa) is linked to higher risks of ischemic stroke, VTE, and acute coronary syndrome (ACS). Contemporary research utilizing coagulometric assays has confirmed FXIa and tissue factor activation in patients with stable coronary artery disease, ACS of less than 12 hours' duration, and heart failure, reinforcing FXI's role as a pathogenic factor in these conditions.

From the patient perspective, the limitations of current DOAC-based strategies extend beyond rare catastrophic haemorrhage to include a spectrum of patient-relevant bleeding and treatment burdens that erode quality of life and adherence. Easy bruising, epistaxis, gingival bleeding, menorrhagia, and minor gastrointestinal bleeding are often labelled nuisance or non-major events in clinical trials, but patients describe these as anxiety-provoking, stigmatizing, and disruptive to daily activities. Such events, together with polypharmacy, twice-daily dosing for some agents, drug drug interactions, and the need for uninterrupted long-term therapy, frequently lead to missed doses, dose reductions, or unsupervised discontinuation of DOACs, which in turn compromises stroke protection at the population level. In parallel, important patient subgroups including those with advanced chronic kidney disease or dialysis, advanced liver disease, prior intracranial haemorrhage, or frailty have been underrepresented in pivotal DOAC trials and often withheld treatment or remain untreated because of bleeding concerns. By targeting FXI, vortosiran has the potential to dissociate pathological thrombosis from physiological haemostasis, and to deliver sustained antithrombotic protection with a lower risk bleeding than currently available therapies and an adherence profile that is better aligned with patients' priorities and lived experience.

Clinical trials targeting FXI inhibition in the context of cardiovascular disease, including AF, are ongoing or recently completed. Several Phase 2 and 3 trials are investigating FXI/FXIa inhibitors by use of different modalities such as monoclonal antibodies and small molecules across multiple high-risk groups, evaluating efficacy and bleeding outcomes against standard anticoagulants for stroke prevention in AF (SPAF). These studies collectively support the notion that FXI/FXIa may be a favourable anticoagulation target, capable of reducing thrombotic events with a lower side effect profile, especially bleeding, compared to traditional agents. However, while several trials confirm safety advantages, data on efficacy remain to be further demonstrated, necessitating continued research focus. Vortosiran is an N-acetyl galactosamine (GalNAc) conjugated small interfering ribonucleic acid (siRNA), enabling highly specific and highly durable enrichment of the siRNA in hepatocytes, offering a modality specifically inhibiting the production of FXI. Vortosiran is under development to achieve a durable antithrombotic effect by reducing the levels of FXI.

The rationale for the current trial is based on data from multiple Phase 2 and 3 studies of FXI/FXIa inhibitors that have assessed FXI clotting activity and the effect on venous thrombosis inhibition, and is currently being tested for stroke prevention in atrial fibrillation patients. Based on the collective observations for these studies, that FXI clotting activity inhibition translates into a lower risk of thrombosis with a lower risk of bleeding compared to standard of care, the ongoing Phase 3 studies, and that vortosiran treatment can achieve identical or even higher degrees of FXI clotting activity inhibition, there is a rationale that vortosiran could potentially improve benefit-risk balance for stroke prevention in patients with atrial fibrillation compared to standard of care with FXa inhibitors.

03

Conditions studied

  • Non-valvular Atrial Fibrillation (AF)

Browse trials for

Keywords

  • AF
  • Atrial fibrillation
  • siRNA
  • Phase 2
  • RCT
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult male and female participants, age >/=45 years.
  2. Documented diagnosis of non-valvular AF within 12 months of signing the (paroxysmal, persistent, or permanent) confirmed by evidence (12-lead or other physician-confirmed electronic recording) and currently receiving continuous treatment with a DOAC for stroke prevention for at least the past 3 months.
  3. Capable of giving signed informed consent. Written informed consent must be obtained before any trial procedure is initiated.
  4. women are eligible without additional measures. Postmenopausal status is defined as:

    • Age >/=55 years with >/=12 months of spontaneous amenorrhea, or
    • Age \<55 years with >/=12 months of spontaneous amenorrhea and follicle-stimulating hormone in the postmenopausal range, or surgical menopause (bilateral oophorectomy, with or without hysterectomy) documented in the medical history.
  5. Women of must agree to use highly effective contraception for the duration of trial treatment and for the specified post-treatment period.

Exclusion criteria

Exclusion Criteria:

  1. AF due to a reversible cause (e.g., cardiac surgery, pulmonary embolism, untreated hyperthyroidism, alcohol use), participants in sinus rhythm after successful ablation or planned for cardioversion or ablation during trial conduct.
  2. Patients with an intracranial or intraocular bleed within the 3 months prior to screening or any history of spontaneous intracerebral haemorrhage at any time in the absence of antithrombotic treatment.
  3. Any stroke within 14 days before randomisation or a within 3 days before randomisation.
  4. Mechanical heart valve or valve disease that is expected to require mechanical valve replacement intervention (surgical or trans vascular) during the course of the trial.
  5. Patients with a medical condition other than non-valvular AF for which chronic anticoagulation is indicated.
  6. Known presence of an atrial myxoma or left ventricular thrombus.
  7. History of or planned left atrial appendage closure or left atrial appendage removal.
  8. Uncontrolled hypertension (systolic blood pressure >/= 160 mmHg or diastolic blood pressure >/=100 mmHg) at randomization.
  9. Active bleeding, known bleeding disorder, or known anaemia that requires treatment or capillary \<100 g/L.
  10. Any history of non-traumatic intracranial haemorrhage when not under treatment with an anticoagulant.
  11. Known significant liver disease (e.g., acute hepatitis, chronic active hepatitis, cirrhosis) or hepatic insufficiency classified as B or C, or (ALT)/aspartate aminotransferase (AST) >2.5 x the , measured between screening and randomisation.
  12. Estimated (eGFR) \< 30 mL/min/1.73 m2 from the local lab, determined between screening and randomization.
  13. Major surgery during the last 30 days or planned major surgery or intervention with potential for uncontrolled bleeding within the trial period (e.g., carotid endarterectomy, coronary artery bypass grafting).
  14. Women who are pregnant, currently breastfeeding, or planning pregnancy during the trial or within the defined post-treatment period are not eligible.
  15. Known allergy, intolerance, or to any of the trial interventions.
  16. Any for the use of an anticoagulant or listed in the local labelling for apixaban.
  17. Anticipated need for chronic therapy with nonsteroidal anti-inflammatory drugs (NSAIDs): Patients with chronic NSAID use, defined as systemic NSAID therapy on >/=3 days per week for at least 4 consecutive weeks prior to screening, are excluded.
  18. Treated with a vitamin K antagonist within 3 months prior to screening.
  19. Patients with a diagnosis of virus (HBV), virus (HCV) or (HIV) at screening.
  20. Known current alcohol and / or illicit drug abuse that may interfere with the participant's safety and / or compliance at the discretion of the Investigator.
  21. Male participants who are not willing to use condoms when sexually active with a woman of who is not using highly effective .
  22. Previous (within 30 days or 5 half-lives of the drug, whichever is longer) or concomitant participation in another clinical trial with investigational medicinal product(s) or device(s). Registries and observational studies are allowed.
  23. Any other condition or therapy that would make the participant unsuitable for the trial.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Active comparator
    Low dose group receiving vortosiran.

    The low-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, the participants will start an open-label part of the trial and receive apixaban until the end of the trial.

    Drug: Vortosiran

  • Active comparator
    High dose group receiving vortosiran.

    The low-dose group will receive two doses of vortosiran, the first dose at Day X and the second at Day Y. After 24 weeks, the participants will start an open-label part of the trial and receive apixaban until the end of the trial.

    Drug: Vortosiran

  • Active comparator
    Group receiving apixaban

    The third treatment group will receive apixaban during the entire trial.

    Drug: Apixaban

Interventions

  • DrugVortosiran

    Vortosiran, active drug

  • DrugVortosiran

    Vortosiran, active drug

  • Comparator, active drug

06

What researchers measure

Primary outcomes

  1. Primary objective

    To evaluate the effect of vortosiran on change in coagulation Factor XI (FXI) activity

    Time frame: At week 16

  2. Primary endpoint

    Change in FXI blood coagulation activity.

    Time frame: At week 16

Secondary outcomes

  1. Secondary objective

    To evaluate the safety, including the frequency and severity of bleeding events, with vortosiran, when administered subcutaneously as repeated doses, in participants with non-valvular AF, when compared to apixaban.

    Time frame: From screening until end of trial at week 64

  2. Secondary objective

    To evaluate the safety, including the frequency and severity of bleeding events, with vortosiran, when administered subcutaneously to patients concomitantly taking apixaban, in participants with AF

    Time frame: From screening until end of trial at week 64

  3. Secondary objective

    Change in FXI blood coagulation activity

    Time frame: At week 64

  4. Secondary objective

    To assess plasma exposure of vortosiran in participants with non-valvular AF

    Time frame: 0 (pre-dose) to 24 hours after dosing

  5. Secondary objective

    Number of participants with positive anti-drug antibodies (ADAs)

    Time frame: At week 64

  6. Secondary objective

    Change from baseline in APTT measurement throughout the trial period.

    Time frame: From baseline to week 64

  7. Secondary objective

    Change and percent change compared with pre-dose baseline of PT-INR coagulation activity in each treatment group.

    Time frame: From baseline to week 64

07

Study locations

15 sites
  • Frederiksberg Hospital
    Frederiksberg, Denmark
    • Thomas Hermann, Doctor · Contact
    • Thomas Hermann, Doctor · Principal investigator
  • Herlev-Gentofte
    Herlev, Denmark
  • Sykehuset Østfold Kalnes Kardiologisk
    Grålum, Norway
  • Akershus Universitetssykehus Ahus Kardiologisk
    Lørenskog, Norway
  • EMC Silesia spółka z ograniczoną odpowiedzialnością
    Katowice, Poland
  • Centrum Medyczne Vitamedicum
    Krakow, Poland
  • Balsam Medica Sp z o.o.
    Raszyn, Poland
    • Pawel Balsam, Doctor · Contactpawel.balsam@me.com
    • Pawel Balsam, Doctor · Principal investigator
  • Aidport Clinical Trial Hospital
    Skorzewo, Poland
  • Centrum Medyczne LUX MED
    Warsaw, Poland
  • Centrum Badań Klinicznych
    Wroclaw, Poland
  • Centrum Medyczne Oporów
    Wroclaw, Poland
  • Pracownia Badan Klinicznych Salus
    Wroclaw, Poland
  • Danderyds Sjukhus - Hjärtmottagningen
    Danderyd, Sweden
    • Mika Skeppholm, Doctor · Contact
    • Mika Skeppholm, Doctor · Principal investigator
  • SUS Lund, Department of Cardiology
    Lund, Sweden
  • Södersjukhuset, Department of Cardiology
    Stockholm, Sweden
    • Raffaele Scorza, Doctor · Contact
    • Raffaele Scorza, Doctor · Principal investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Jul 2028, 21 months later.

Of 41 phase 2 interventional studies under Atrial Fibrillation, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 39. This study's planned 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 29, 2026
First posted
Oct 13, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Jul 31, 2028
CompletionEst.
Aug 31, 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07870889
Collaborators
Link Medical Research AB
Responsible party
Sponsor
First posted
Oct 13, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Jul 31, 2028 (estimated)
Completion
Aug 31, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Rebeckha Magnusson, Head Clinical Operations
Contact
rebeckha.magnusson@ribocure.com
+46 31 72 07 800
Anders Gabrielsen, MD, PhD
study director · Ribocure Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Apixaban

Start the discussion